Metabolic Syndrome Clinical Trial
Official title:
the Association Between Serum Uric Acid Levels and the Risk of Metabolic Syndrome in Type 2 Diabetes Mellitus
This study will be undertaken to evaluate the association of serum uric acid (SUA) level with metabolic risk factors in patients with type 2 diabetes and their relation to eGFR status
Metabolic syndrome (syndrome X, insulin resistance) is a multifactorial disease with multiple
risk factors that arises from insulin resistance accompanying abnormal adipose deposition and
function . It comprises a combination of risk factors for coronary heart disease, as well as
for diabetes type 2 , fatty liver, and several cancers.
Sign and symptoms are ; Hypertension... Hyperglycemia.. Hypertriglyceridemia... Reduced
high-density lipoprotein cholesterol (HDL-C).. Abdominal obesity... Chest pain or shortness
of breath: Suggesting the rise of cardiovascular and other complications.. The prevalence of
the metabolic syndrome is often more in the urban population of some developing countries
than in its Western counterparts . The syndrome feeds into the spread of the diseases like
type 2 diabetes, coronary diseases, stroke, and other disabilities. The present trend is not
sustainable unless a magic cure is found (unlikely) or concerted global/governmental/societal
efforts are made to change the lifestyle that is promoting it.
There has been a renewed interest in the association of uric acid with diabetes and its
complications. Uric acid is a product of purine metabolism. Increased serum uric acid (SUA)
level has been shown to be associated with hypertension(1) cardiovascular disease (CVD)(2)
and chronic kidney disease(3) . Elevated SUA level was also associated with metabolic
syndrome in both normal subjects as well as in patients with type 2 diabetes. And with type 2
diabetes mellitus(4) Higher SUA level independently predicted the incidence of type 2
diabetes in subjects who had abnormal fasting glucose levels (5) . It has been shown that SUA
levels are higher in patients with prediabetic conditions and in patients with type 2
diabetes compared with the level in normal controls (6) . SUA level has been shown to be
positively associated with all cause mortality risk, but cardiovascular mortality was
associated with SUA level only among those with hyperglycemia (prediabetes and type 2
diabetes)(8) . Hyperuricemia has been found to be associated with risk factors of diabetes
such as obesity and insulin resistance(9) . Uric acid has also been reported to be involved
in the endothelial dysfunction by impairing nitric oxide production and causing
inflammation(10) , These effects of uric acid likely account for its impact on CVD
incidence(11) . In acute ischaemic stroke, the survivors with both lower (<4.7 mg/dL) and
higher (>6.7 mg/dL) baseline SUA levels had poor outcomes after a 12 month follow up when
compared with those who had SUA levels in the range of 4.7-6.7 mg/dL. This is suggestive of
the protective nature of uric acid when it is within the optimal range.
SUA level was positively associated with increased incidence of cardiovascular diseases (CVD)
in patients with abnormal eGFR (<90 mL/min/1.73 m2) . HbA1c was found to be inversely
associated with hyperuricemia in patients with normal eGFR level (≥90 mL/min/1.73 m2).
Incidence of metabolic syndrome did not show any relationship with SUA level. However, the
incidence of hypertension, a component of metabolic syndrome, was significantly higher among
patients with hyperuricemia. Waist circumference and serum triglycerides were higher, whereas
serum high-density lipoprotein level was lower in patients with higher SUA level. (12) Serum
urea and creatinine were elevated in hyperuricemic patients, suggesting impaired kidney
function. Hyperuricemia is known to be associated with the decrease in kidney function (13)
and because chronic kidney disease itself elevates SUA level,(14) it is difficult to
interpret the causes of the elevated serum urea and creatinine in hyperuricemia. However,
eGFR values were only slightly lower in hyperuricemic patients. Correlation analysis showed
that both serum urea and creatinine levels were positively associated with SUA level.. This
association was found to be significant in patients with normal eGFR levels as well. However,
eGFR appears to be negatively associated with SUA level in patients with abnormal eGFR level.
Decreased urine output leads to decreased excretion of uric acid, resulting in the elevated
SUA level. Therefore, reduction in eGFR may increase SUA levels in these patients.
The importance of uric acid has been increasingly appreciated because of its association with
the development of diabetes mellitus and related diseases. SUA level and susceptibility to
hyperuricemic conditions depend on the factors such as gender, age and ethnicity. (15) With
the increasing incidence of diabetes studying the impact of hyperuricemia in patients with
diabetes is necessary.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04635202 -
Effect of Elliptical Training on Metabolic Homeostasis in Metabolic Syndrome
|
N/A | |
Completed |
NCT05343858 -
Pilot Study to Evaluate the Effect of Two Microalgae Consumption on Metabolic Syndrome
|
N/A | |
Completed |
NCT04053686 -
An Intervention to Reduce Prolonged Sitting in Police Staff
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Recruiting |
NCT05040958 -
Carotid Atherosclerotic Plaque Load and Neck Circumference
|
||
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Recruiting |
NCT05956886 -
Sleep Chatbot Intervention for Emerging Black/African American Adults
|
N/A | |
Completed |
NCT06057896 -
Effects of Combined Natural Molecules on Metabolic Syndrome in Menopausal Women
|
||
Active, not recruiting |
NCT03613740 -
Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion
|
Phase 2 | |
Completed |
NCT04498455 -
Study of a Prebiotic Supplement to Mitigate Excessive Weight Gain Among Physicians in Residency
|
Phase 4 | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Completed |
NCT03697382 -
Effect of Daily Steps on Fat Metabolism
|
N/A | |
Completed |
NCT03241121 -
Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome
|
N/A | |
Completed |
NCT04509206 -
Virtual Teaching Kitchen
|
N/A | |
Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A |